Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Classifica tra le azioni
#3774
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Prezzo delle azioni
$4.87
Capitalizzazione di mercato
$4.36B
Variazione (1 giorno)
-5.47%
Variazione (1 anno)
-15.62%
Paese
CN
Scambia Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Categoria
Healthcare
Rapporto P/S per Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Rapporto P/S al October 2026 TTM: 6.59
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, il rapporto P/S attuale (TTM) è 6.59. Alla fine del 2024, era pari a 11.09.
Storico del rapporto P/S per Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd da 2006 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 6.59 | 9.03% |
| 2025 | 6.04 | -45.55% |
| 2024 | 11.09 | -17.86% |
| 2023 | 13.50 | 42.44% |
| 2022 | 9.48 | -21.14% |
| 2021 | 12.02 | -45.65% |
| 2020 | 22.12 | -9.73% |
| 2019 | 24.50 | 0.76% |
| 2018 | 24.32 | -3.03% |
| 2017 | 25.08 | -11.90% |
| 2016 | 28.47 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 46.19 | -21.47% |
| 2011 | 58.81 | -21.40% |
| 2010 | 74.82 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.72 | 62.80% |
US
|
|
| 41.70 | 533.21% |
US
|
|
| 4.19 | -36.36% |
AU
|
|
| 5.80 | -12.00% |
BE
|
|
| 10.44 | 58.57% |
NL
|
